Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients
(2021) In Allergy: European Journal of Allergy and Clinical Immunology 76(5). p.1528-1538- Abstract
Background: Allergic rhinoconjunctivitis is a public health problem. Allergen Immunotherapy is an effective and safe treatment, that modifies the natural course of allergic disease and induces long-term tolerance. Objective: To correlate basophil and antibody biomarkers of subcutaneous immunotherapy to clinical outcomes and cellular changes in target tissue. Methods: Adults suffering from allergic rhinoconjunctivitis due to grass pollen allergy were randomized to receive subcutaneous immunotherapy (n = 18) or to an open control group (n = 6). Patients reported daily symptom and medication scores and weekly rhinitis related quality of life scores during four pollen seasons. Biomarkers were measured every 3 months for three years... (More)
Background: Allergic rhinoconjunctivitis is a public health problem. Allergen Immunotherapy is an effective and safe treatment, that modifies the natural course of allergic disease and induces long-term tolerance. Objective: To correlate basophil and antibody biomarkers of subcutaneous immunotherapy to clinical outcomes and cellular changes in target tissue. Methods: Adults suffering from allergic rhinoconjunctivitis due to grass pollen allergy were randomized to receive subcutaneous immunotherapy (n = 18) or to an open control group (n = 6). Patients reported daily symptom and medication scores and weekly rhinitis related quality of life scores during four pollen seasons. Biomarkers were measured every 3 months for three years treatment and every 6 months in the follow-up year. Nasal and cutaneous allergen challenge tests were performed annually. Leukocyte subsets were assessed in nasal mucosa biopsies at baseline and after treatment. Results: Subcutaneous immunotherapy led to a 447-fold decrease in basophil sensitivity during the first treatment year. This remained 100-fold lower than baseline during the 3 year-treatment period and 10-fold lower during the follow-up year (n = 18, P =.03). Decrease in basophil sensitivity after three weeks of treatment predicted long-term improvement in seasonal combined symptom and medication scores (ῥ=−0.69, P =.0027) during three years of treatment. AUC of IgE-blocking factor correlated to nasal allergen challenge (ῥ = 0.63, P =.0012) and SPT (ῥ = 0.45, P =.03). Plasma cell numbers in the nasal mucosa increased during treatment (P =.02). Conclusion: Decrease in basophil sensitivity after three weeks of subcutaneous allergen immunotherapy predicted the clinical outcome of this treatment.
(Less)
- author
- Schmid, Johannes M. ; Würtzen, Peter A. ; Siddhuraj, Premkumar LU ; Jogdand, Prajakta LU ; Petersen, Claus G. ; Dahl, Ronald ; Erjefält, Jonas S. LU and Hoffmann, Hans Jürgen
- organization
- publishing date
- 2021-05-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- allergen-specific IgE, basophil activation test, basophil sensitivity measurement, facilitated antigen binding, IgE-blocking factor
- in
- Allergy: European Journal of Allergy and Clinical Immunology
- volume
- 76
- issue
- 5
- pages
- 11 pages
- publisher
- Wiley-Blackwell
- external identifiers
-
- scopus:85082039301
- pmid:32145088
- ISSN
- 0105-4538
- DOI
- 10.1111/all.14264
- language
- English
- LU publication?
- yes
- id
- 0764d16d-64d9-4f40-8787-7f560b912abc
- date added to LUP
- 2020-04-09 08:44:08
- date last changed
- 2024-06-26 13:24:27
@article{0764d16d-64d9-4f40-8787-7f560b912abc,
abstract = {{<p>Background: Allergic rhinoconjunctivitis is a public health problem. Allergen Immunotherapy is an effective and safe treatment, that modifies the natural course of allergic disease and induces long-term tolerance. Objective: To correlate basophil and antibody biomarkers of subcutaneous immunotherapy to clinical outcomes and cellular changes in target tissue. Methods: Adults suffering from allergic rhinoconjunctivitis due to grass pollen allergy were randomized to receive subcutaneous immunotherapy (n = 18) or to an open control group (n = 6). Patients reported daily symptom and medication scores and weekly rhinitis related quality of life scores during four pollen seasons. Biomarkers were measured every 3 months for three years treatment and every 6 months in the follow-up year. Nasal and cutaneous allergen challenge tests were performed annually. Leukocyte subsets were assessed in nasal mucosa biopsies at baseline and after treatment. Results: Subcutaneous immunotherapy led to a 447-fold decrease in basophil sensitivity during the first treatment year. This remained 100-fold lower than baseline during the 3 year-treatment period and 10-fold lower during the follow-up year (n = 18, P =.03). Decrease in basophil sensitivity after three weeks of treatment predicted long-term improvement in seasonal combined symptom and medication scores (ῥ=−0.69, P =.0027) during three years of treatment. AUC of IgE-blocking factor correlated to nasal allergen challenge (ῥ = 0.63, P =.0012) and SPT (ῥ = 0.45, P =.03). Plasma cell numbers in the nasal mucosa increased during treatment (P =.02). Conclusion: Decrease in basophil sensitivity after three weeks of subcutaneous allergen immunotherapy predicted the clinical outcome of this treatment.</p>}},
author = {{Schmid, Johannes M. and Würtzen, Peter A. and Siddhuraj, Premkumar and Jogdand, Prajakta and Petersen, Claus G. and Dahl, Ronald and Erjefält, Jonas S. and Hoffmann, Hans Jürgen}},
issn = {{0105-4538}},
keywords = {{allergen-specific IgE; basophil activation test; basophil sensitivity measurement; facilitated antigen binding; IgE-blocking factor}},
language = {{eng}},
month = {{05}},
number = {{5}},
pages = {{1528--1538}},
publisher = {{Wiley-Blackwell}},
series = {{Allergy: European Journal of Allergy and Clinical Immunology}},
title = {{Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients}},
url = {{http://dx.doi.org/10.1111/all.14264}},
doi = {{10.1111/all.14264}},
volume = {{76}},
year = {{2021}},
}